title: Developmental programming: impact of prenatal testosterone excess on ovarian cell proliferation and apoptotic factors in sheep.
abstract: Prenatal testosterone (T) excess leads to reproductive dysfunctions in sheep, which include increased ovarian follicular recruitment and persistence. To test the hypothesis that follicular disruptions in T sheep stem from changes in the developmental ontogeny of ovarian proliferation and apoptotic factors, pregnant Suffolk sheep were injected twice weekly with T propionate or dihydrotestosterone propionate (DHT; a nonaromatizable androgen) from Days 30 to 90 of gestation. Changes in developmental expression of proliferating cell nuclear antigen (PCNA), BCL2, BAX, activated CASP3, and FAS/FASLG were determined at Fetal Days 90 and 140, 22 wk, 10 mo, and 21 mo of age by immunocytochemisty. Prenatal T treatment induced changes in expression of proliferative and apoptotic markers in a follicle-, age-, and steroid-specific manner. Changes in BAX were evident only during fetal life and PCNA, BCL2, and CASP3 only postnatally. Prenatal T and not DHT increased PCNA and decreased BCL2 in granulosa/theca cells of antral follicles at 10 and 21 mo but decreased CASP3 in granulosa/theca cells of antral follicles at 22 wk (prepubertal) and 10 and 21 mo. Both treatments decreased BAX immunostaining in granulosa cells of Fetal Day 90 primordial/primary follicles. Neither treatment affected FAS expression at any developmental time point in any follicular compartment. Effects on BAX appear to be programmed by androgenic actions and PCNA, BCL2, and CASP3 by estrogenic actions of T. Overall, the findings demonstrate that fetal exposure to excess T disrupts the ovarian proliferation/apoptosis balance, thus providing a basis for the follicular disruptions evidenced in these females.
authors.affiliation: Department of Morphological Sciences, Faculty of Veterinary Sciences, National University of Litoral, Esperanza, Argentina.
authors.forename: Natalia R
authors.initials: NR
authors.lastname: Salvetti
authors.forename: Hugo H
authors.initials: HH
authors.lastname: Ortega
authors.forename: Almudena
authors.initials: A
authors.lastname: Veiga-Lopez
authors.forename: Vasantha
authors.initials: V
authors.lastname: Padmanabhan
mesh_terms: D000818:Animals; D017209:Apoptosis / Q000187:drug effects / Q000502:physiology; D053148:Caspase 3 / Q000378:metabolism; D049109:Cell Proliferation / Q000187:drug effects; D013196:Dihydrotestosterone / Q000008:administration & dosage / Q000031:analogs & derivatives; D053222:Fas Ligand Protein / Q000378:metabolism; D005260:Female; D006801:Humans; D010053:Ovary / Q000187:drug effects* / Q000473:pathology* / Q000503:physiopathology; D011247:Pregnancy; D011297:Prenatal Exposure Delayed Effects / Q000473:pathology* / Q000503:physiopathology; D018809:Proliferating Cell Nuclear Antigen / Q000378:metabolism; D019253:Proto-Oncogene Proteins c-bcl-2 / Q000378:metabolism; D012756:Sheep; D043343:Testosterone Propionate / Q000008:administration & dosage*; D057170:Translational Research, Biomedical; D019014:fas Receptor / Q000378:metabolism
chemical_list: D053222:Fas Ligand Protein; D018809:Proliferating Cell Nuclear Antigen; D019253:Proto-Oncogene Proteins c-bcl-2; D019014:fas Receptor; D013196:Dihydrotestosterone; C030445:dihydrotestosterone propionate; D053148:Caspase 3; D043343:Testosterone Propionate